
## Shuguang Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3640480/publications.pdf Version: 2024-02-01



SHUCHANG TAN

#	Article	IF	CITATIONS
1	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, 2020, 63, 364-374.	2.3	1,606
2	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science, 2020, 368, 1274-1278.	6.0	964
3	Nanozyme-strip for rapid local diagnosis of Ebola. Biosensors and Bioelectronics, 2015, 74, 134-141.	5.3	320
4	Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review, 2020, 7, 1003-1011.	4.6	202
5	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 2017, 8, 14369.	5.8	192
6	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6640-6650.	3.3	141
7	Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nature Communications, 2014, 5, 3595.	5.8	137
8	Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Research, 2017, 27, 151-153.	5.7	116
9	Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein and Cell, 2018, 9, 135-139.	4.8	107
10	CD8 <sup>+</sup> T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection. Journal of Virology, 2017, 91, .	1.5	102
11	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. Cell, 2021, 184, 3438-3451.e10.	13.5	100
12	The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Scientific Reports, 2015, 5, 10942.	1.6	93
13	Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein. Cell, 2019, 177, 1714-1724.e12.	13.5	75
14	Cross-species recognition of SARS-CoV-2 to bat ACE2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	73
15	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 2017, 8, 67129-67139.	0.8	65
16	A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communications, 2021, 12, 776.	5.8	65
17	Clinical and Immunological Characteristics of Human Infections With H5N6 Avian Influenza Virus. Clinical Infectious Diseases, 2019, 68, 1100-1109.	2.9	56
18	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduction and Targeted Therapy, 2016, 1, 16029.	7.1	53

Shuguang Tan

#	Article	IF	CITATIONS
19	Nâ€glycosylation of PDâ€1 promotes binding of camrelizumab. EMBO Reports, 2020, 21, e51444.	2.0	47
20	Cross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive Individuals. Journal of Virology, 2012, 86, 13281-13294.	1.5	45
21	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	4.8	44
22	The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	40
23	Structures of the fourÂlg-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular and Molecular Immunology, 2020, 17, 966-975.	4.8	38
24	An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nature Immunology, 2022, 23, 423-430.	7.0	38
25	Conserved epitopes dominate crossâ€ <scp>CD</scp> 8 <sup>+</sup> <scp>T</scp> â€cell responses against influenza <scp>A H</scp> 1 <scp>N</scp> 1 virus among <scp>A</scp> sian populations. European Journal of Immunology, 2013, 43, 2055-2069.	1.6	37
26	Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development. Experimental Biology and Medicine, 2011, 236, 253-267.	1.1	35
27	An unexpected similarity between antibiotic-resistant NDM-1 and beta-lactamase II from Erythrobacter litoralis. Protein and Cell, 2011, 2, 250-258.	4.8	34
28	Two classes of protective antibodies against Pseudorabies virus variant glycoprotein B: Implications for vaccine design. PLoS Pathogens, 2017, 13, e1006777.	2.1	34
29	The FG Loop of PD-1 Serves as a "Hotspot―for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. IScience, 2019, 14, 113-124.	1.9	34
30	Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Reports, 2018, 25, 909-920.e4.	2.9	33
31	Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and virological findings. Journal of Infection, 2019, 78, 241-248.	1.7	31
32	Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. International Journal of Biological Sciences, 2021, 17, 4073-4091.	2.6	31
33	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs, 2019, 11, 681-690.	2.6	30
34	Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes. Molecular Immunology, 2011, 49, 395-401.	1.0	29
35	The identification of a CD47-blocking "hotspot―and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduction and Targeted Therapy, 2020, 5, 16.	7.1	29
36	Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. Emerging Microbes and Infections, 2020, 9, 1238-1241.	3.0	26

Shuguang Tan

#	Article	IF	CITATIONS
37	Prolonged Evolution of Virus-Specific Memory T Cell Immunity after Severe Avian Influenza A (H7N9) Virus Infection. Journal of Virology, 2018, 92, .	1.5	25
38	Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses. MBio, 2018, 9, .	1.8	25
39	Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 988-996.	3.3	25
40	Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions. Journal of Infectious Diseases, 2016, 214, 1937-1946.	1.9	24
41	Nosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders. Emerging Infectious Diseases, 2016, 22, 598-607.	2.0	23
42	Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses. Nature Communications, 2020, 11, 5964.	5.8	22
43	VP2 Dominated CD4+ T Cell Responses against Enterovirus 71 and Cross-Reactivity against Coxsackievirus A16 and Polioviruses in a Healthy Population. Journal of Immunology, 2013, 191, 1637-1647.	0.4	21
44	Structural basis for the differential classification of HLA-A*6802 and HLA-A*6801 into the A2 and A3 supertypes. Molecular Immunology, 2013, 55, 381-392.	1.0	20
45	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 826045.	2.2	13
46	Hemagglutinin-specific CD4 + T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine, 2017, 35, 5644-5652.	1.7	10
47	Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by Acinetobacter Baumannii: a case control study. BMC Infectious Diseases, 2018, 18, 664.	1.3	8
48	Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Signal Transduction and Targeted Therapy, 2020, 5, 158.	7.1	8
49	Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy. Frontiers in Immunology, 2021, 12, 644520.	2.2	8
50	CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection. Tuberculosis, 2017, 107, 5-12.	0.8	5
51	Avian influenza viruses suppress innate immunity by inducing trans-transcriptional readthrough via SSU72. , 2022, 19, 702-714.		5
52	Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for TÂcell activation. Cell Reports, 2021, 36, 109734.	2.9	3
53	Reply to "Nuclear Export Signal and Immunodominant CD8+T Cell Epitope in Influenza A Virus Matrix Protein 1― Journal of Virology, 2012, 86, 10259-10260.	1.5	1
54	Pneumonia Severity and Phase Linked to Virus-Specific T Cell Responses with Distinct Immune Checkpoints during pH1N1 Infection. Journal of Immunology, 2022, , ji2101021.	0.4	0